Acceleron Pharma Inc.
Endoglin polypeptides and uses thereof
Last updated:
Abstract:
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders.
Status:
Grant
Type:
Utility
Filling date:
28 Feb 2018
Issue date:
20 Apr 2021